Dr. Lal Pathlabs Limited
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Healthy return on equity of 20.2%
Concerns1
- Negative free cash flow (βΉ78 Cr)
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ2.35 K Cr | β | βΉ497.00 Cr | β | β | 23.3% | 19.6% | 29.4% |
| Mar 2024 | βΉ1.97 K Cr | β | βΉ384.00 Cr | β | β | 20.2% | 11.2% | 31.5% |
| Mar 2023 | βΉ1.77 K Cr | β | βΉ292.00 Cr | β | β | 17.3% | -5.6% | -15.1% |
| Mar 2022 | βΉ1.87 K Cr | β | βΉ344.00 Cr | β | β | 23.3% | 25.6% | 22.9% |
| Mar 2021 | βΉ1.49 K Cr | β | βΉ280.00 Cr | β | β | 23.0% | 17.0% | 25.6% |
| Mar 2020 | βΉ1.27 K Cr | β | βΉ223.00 Cr | β | β | 21.9% | 9.4% | 14.4% |
| Mar 2019 | βΉ1.17 K Cr | β | βΉ195.00 Cr | β | β | 21.0% | 13.8% | 16.1% |
| Mar 2018 | βΉ1.02 K Cr | β | βΉ168.00 Cr | β | β | 21.6% | 16.1% | 10.5% |
| Mar 2017 | βΉ882.00 Cr | β | βΉ152.00 Cr | β | β | 25.9% | 15.3% | 20.6% |
| Mar 2016 | βΉ765.00 Cr | β | βΉ126.00 Cr | β | β | 26.3% | 20.1% | 37.0% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 2,487 |
| Total Expenses | 1,778 |
| EBIT / Operating Profit | 709 |
| OPM % | 28% |
| Other Income | 106 |
| Finance Costs | 19 |
| Depreciation & Amortisation | 140 |
| Profit Before Tax | 656 |
| Tax % | - |
| Net Profit / PAT | 529 |
| EPS (βΉ) | 31.58 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Dr. Lal Pathlabs Limitedthis co. | βΉ23.78 K Cr | βΉ2.35 K Cr | 45.00 | 10.15 | 38.33 | 19.6% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |